These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 33804613)

  • 1. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma.
    Rebelo R; Polónia B; Santos LL; Vasconcelos MH; Xavier CPR
    Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33804613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates.
    De Lellis L; Veschi S; Tinari N; Mokini Z; Carradori S; Brocco D; Florio R; Grassadonia A; Cama A
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing some of the Well-known Non-steroid Anti-inflammatory Drugs (NSAIDs) for Cancer Treatment.
    Sousa SM; Xavier CPR; Vasconcelos MH; Palmeira A
    Curr Top Med Chem; 2023; 23(13):1171-1195. PubMed ID: 36717997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
    Veschi S; De Lellis L; Florio R; Lanuti P; Massucci A; Tinari N; De Tursi M; di Sebastiano P; Marchisio M; Natoli C; Cama A
    J Exp Clin Cancer Res; 2018 Sep; 37(1):236. PubMed ID: 30241558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug repurposing: An emerging strategy in alleviating skin cancer.
    Kumbhar P; Kole K; Yadav T; Bhavar A; Waghmare P; Bhokare R; Manjappa A; Jha NK; Chellappan DK; Shinde S; Singh SK; Dua K; Salawi A; Disouza J; Patravale V
    Eur J Pharmacol; 2022 Jul; 926():175031. PubMed ID: 35580707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs).
    Renz BW; D'Haese JG; Werner J; Westphalen CB; Ilmer M
    Med Sci (Basel); 2017 Jun; 5(2):. PubMed ID: 29099030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    Singh RR; O'Reilly EM
    Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine.
    Ayasun R; Saridogan T; Gaber O; Sahin IH
    Clin Colorectal Cancer; 2023 Mar; 22(1):2-11. PubMed ID: 36418197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment.
    Liu J; Wu W; Zhu Q; Zhu H
    Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the
    Liu LW; Hsieh YY; Yang PM
    J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32947833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
    Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
    Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities.
    Chakrabarti S; Kamgar M; Mahipal A
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
    Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.
    Mohi-Ud-Din R; Chawla A; Sharma P; Mir PA; Potoo FH; Reiner Ž; Reiner I; Ateşşahin DA; Sharifi-Rad J; Mir RH; Calina D
    Eur J Med Res; 2023 Sep; 28(1):345. PubMed ID: 37710280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.